Showing results (41-50 of 241) with videos related to

Sort By:
Pageof 25
Investigational New Drugs|February 15, 2017
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumorsMonica Mita, Siqing Fu, Sarina Anne Piha-Paul, et al.
Cancer|May 4, 2011
Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center ExperienceAung Naing, Saneese K Stephen, Moshe Frenkel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2010
Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatmentIgnacio Garrido-Laguna, Filip Janku, Gerald S Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials programSiqing Fu, David S Hong, Aung Naing, et al.
Clinical Colorectal Cancer|January 7, 2011
Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastasesLuis H Camacho, Sheila Garcia, Amar M Panchal, et al.
Frontiers in Oncology|February 20, 2018
Corrigendum: Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer CellsYanfang Li, Tao Liu, Cristina Ivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2012
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experienceJennifer Wheler, Apostolia M Tsimberidou, David Hong, et al.
Frontiers in Oncology|March 23, 2013
Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer CellsYanfang Li, Tao Liu, Cristina Ivan, et al.
Oncotarget|June 27, 2013
Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implicationsYunyun Jiang, Filip Janku, Vivek Subbiah, et al.
Cancer|August 9, 2011
Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer CenterIgnacio Garrido-Laguna, Filip Janku, Christos Vaklavas, et al.
Pageof 25